Repository logo
 

Large variation in radiation therapy fractionation for multiple myeloma in Australia.

cam.issuedOnline2022-05-22
dc.contributor.authorOng, Wee Loon
dc.contributor.authorMacManus, Michael
dc.contributor.authorMilne, Roger L
dc.contributor.authorForoudi, Farshad
dc.contributor.authorMillar, Jeremy L
dc.contributor.orcidOng, Wee Loon [0000-0001-6657-7193]
dc.date.accessioned2022-05-23T08:00:22Z
dc.date.available2022-05-23T08:00:22Z
dc.date.issued2023-02
dc.date.submitted2021-07-13
dc.date.updated2022-05-23T08:00:21Z
dc.description.abstractAIM: To evaluate the patterns of use of different radiation therapy (RT) fractionation for multiple myeloma (MM) bone disease. METHODS: This is a population-based cohort of patients with MM who had RT between 2012 and 2017 as captured in the statewide Victorian Radiotherapy Minimum Data Set in Australia. Data linkage was performed to identify subsets of RT delivered within 3 months of death. RT fractionation was classified into four groups: single-fraction (SFRT), 2-5, 6-10, and > 10 fractions. Changes in RT fractionation use over time were evaluated with the Cochran-Armitage test for trend. Factors associated with RT fractionation were evaluated using multivariate logistic regressions. RESULTS: Nine hundred and sixty-seven courses of RT were delivered in 623 patients. The proportion of SFRT, 2-5, 6-10 and > 10 fractions RT was 18%, 47%, 28%, and 7%, respectively. There was an increase in the use of 2-5 fractions, from 48% in 2012 to 60% in 2017 (p-trend < .001), with corresponding decrease in the use of 6-10 fractions, from 26% in 2012 to 20% in 2017 (p-trend = .003). Nine percent (40/430) of RT courses at private institutions were SFRT, compared to 25% (135/537) in public institutions (p < .001). In multivariate analyses, treatment in private institution was the strongest predictor of multifraction RT use. SFRT use was more common closer to the end of life-18%, 14%, and 33% of RT within 2-3, 1-2, < 1 month of death, respectively. CONCLUSION: There is increasing use of shorter course RT (2-5 fractions) for MM over time. SFRT use remains low, with large variation in practice.
dc.identifier.doi10.17863/CAM.84808
dc.identifier.eissn1743-7563
dc.identifier.issn1743-7555
dc.identifier.otherajco13783
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/337394
dc.languageen
dc.language.isoeng
dc.publisherWiley
dc.publisher.urlhttp://dx.doi.org/10.1111/ajco.13783
dc.subjectHumans
dc.subjectDose Fractionation, Radiation
dc.subjectMultiple Myeloma
dc.subjectBone Neoplasms
dc.subjectRadiation Oncology
dc.subjectPalliative Care
dc.subjectAustralia
dc.titleLarge variation in radiation therapy fractionation for multiple myeloma in Australia.
dc.typeArticle
dcterms.dateAccepted2022-03-22
prism.publicationNameAsia Pac J Clin Oncol
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1111/ajco.13783

Files

Original bundle
Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
ajco.13783.pdf
Size:
335.55 KB
Format:
Adobe Portable Document Format
Description:
Published version
Licence
http://creativecommons.org/licenses/by-nc-nd/4.0/
No Thumbnail Available
Name:
ajco.13783.xml
Size:
10.4 KB
Format:
Extensible Markup Language
Description:
Bibliographic metadata
Licence
http://creativecommons.org/licenses/by-nc-nd/4.0/